OPCH SHAREHOLDER ALERT: ADEMI LLP INVESTIGATES WHETHER BUYOUT FAIRLY VALUES OPTION CARE HEALTH, INC.

Ademi LLP is investigating CD&R and McKesson’s proposed acquisition of Option Care Health, under which shareholders would receive $32.05 per share and the transaction has an approximately $5.8 billion enterprise value. The firm is examining whether the price is fair, potential insider benefits, restrictions on competing offers and the board’s process; the release does not establish wrongdoing or report a change to the deal terms.

Analysis

The shareholder-firm release is not evidence that the offer is unfair or that a competing bid is likely; these investigations are common after announced takeovers and can create more headlines than economic friction. The proposed $32.05 per-share value is the key near-term anchor, but without OPCH’s trading price, consideration mechanics, termination-fee terms, and closing conditions, the deal spread and probability-weighted upside cannot be assessed.

For OPCH, the practical risk is a wider or more volatile deal spread if litigation seeks disclosure, delays a vote, or surfaces a credible process issue—not an automatic loss of the stated consideration. A superior bid requires both a willing buyer and enough value to overcome contractual protections; the release supplies no evidence of either. For McKesson, the more material question is whether the acquisition’s strategic and financial merits justify its capital commitment and any integration or regulatory burden. If ownership links distribution with infusion services, the combination could strengthen customer reach, but could also prompt competitors to defend accounts through pricing or partnerships; the article does not establish the deal structure or competitive impact.

Over days, expect limited fundamental information from this release. Over 1–3 months, monitor shareholder filings, proxy disclosures, any court action, and deal milestones. Over 6–18 months, assess McKesson’s disclosed returns and execution rather than assuming synergies. The contrarian point: the headline’s “investigation” language may sound like a challenge to deal value, but absent a filing, credible rival offer, or changed terms, it is a weak catalyst. Falsifiers include a materially improved proposal, an adverse court ruling or closing delay, revised transaction terms, or McKesson guidance indicating the acquisition materially changes capital allocation.

Key Decisions for Investors

• Do not trade OPCH as though a topping bid or deal failure is established. First verify the current share price versus the $32.05 stated value, the form of consideration, closing conditions, and any break fee; without these, the risk-adjusted spread is unknown.
• Treat the law-firm release as a monitoring item, not a standalone short thesis on OPCH or MCK. Reassess only if a shareholder complaint is filed, proxy disclosures reveal a concrete process concern, or another bidder emerges.
• For MCK, review the definitive transaction documents and subsequent company disclosures for funding, regulatory conditions, and expected returns. Avoid assigning a synergy or balance-sheet impact until those details are available.
• Catalyst watch over the next 1–3 months: proxy materials, shareholder vote timing, court filings, and any change to consideration or closing probability. A credible competing proposal would invalidate the base case that the announced value is the principal anchor.